SYRE · Spyre Therapeutics, Inc.

Spyre Therapeutics executed a significant capital raise through a public offering of its common stock, securing approximately $463.5 million in gross proceeds. The transaction involved the sale of 6.5 million firm shares and an additional 975,000 shares following the full exercise of the underwriters' over-allotment option, totaling 7.475 million shares at a price of $62.00 per share. The offering priced on April 14, 2026, and closed promptly on April 16, 2026, indicating strong execution and market demand.

The substantial capital injection is designated to advance the company's pipeline, specifically targeting inflammatory bowel disease (IBD) and rheumatic diseases. Management outlined that the funds will support the full spectrum of drug development, including preclinical studies, clinical trials, manufacturing capabilities, and Phase 3 readiness activities for its antibody programs. This financing provides Spyre with the resources necessary to advance its lead assets through critical value-inflection milestones without immediate liquidity concerns. The offering was conducted by a syndicate of reputable underwriters including Jefferies, Goldman Sachs, Evercore, and Guggenheim, utilizing an effective shelf registration statement filed in February 2026.